Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn. More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
SNY
Recent Articles
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More
New Asthma Drug Could Be Game Changer
An asthma drug developed by Sanofi and Regeneron reduced asthma attacks by 87% in a mid-stage drug trial. More
Bulls vs. Bears: Can Biogen Keep Booming?
Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments. More
Intimidated By Your New 401k? Try a Target-Date Fund
Signing up for a 401k is cake, but deciding how to allocate your funds isn't so easy. Target-date mutual funds can shoulder that burden. More
The Best and Worst Mutual Funds of Q1 2013
Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind. More
FDA Approves New Biogen Drug to Treat MS
The Food and Drug Administration has approved Biogen Idec's new multiple sclerosis capsule, Tecfidera. More
